The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Dasatinib–Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults
Open accessAbstract
BACKGROUND: Outcomes in patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) have improved with the use of tyrosine kinase inhibitors. Molecular remission is a primary goal of treatment. METHODS: We conducted a phase 2 single-group trial of first-line therapy in adults with newly diagnosed Ph-positive ALL (with no upper age limit). Dasatinib plus glucocorticoids were administered, followed by two cycles of blinatumomab. The primary end point was a sustained molecular response in the bone marrow after this treatment. RESULTS: mutations were detected in 6 patients who had increased minimal residual disease during induction therapy, and all these mutations were cleared by blinatumomab. Six relapses occurred. Overall, 21 adverse events of grade 3 or higher were recorded. A total of 24 patients received a stem-cell allograft, and 1 death was related to transplantation (4%). CONCLUSIONS: A chemotherapy-free induction and consolidation first-line treatment with dasatinib and blinatumomab that was based on a targeted and immunotherapeutic strategy was associated with high incidences of molecular response and survival and few toxic effects of grade 3 or higher in adults with Ph-positive ALL. (Funded by Associazione Italiana per la Ricerca sul Cancro and others; GIMEMA LAL2116 D-ALBA EudraCT number, 2016-001083-11; ClinicalTrials.gov number, NCT02744768.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Harris, P. A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., & Conde, J. G. (2009) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2008.08.010 · Cited by 51,384
The REDCap consortium: building an international community of software platform partners
Harris, P. A., Taylor, R., Minor, B. L., Elliott, V., Fernandez, M., O'Neal, L., McLeod, L., Delacqua, G., Delacqua, F., Kirby, J., et al. (2019) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2019.103208 · Cited by 24,013
Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia
Mullighan, C. G., Su, X., Zhang, J., Radtke, I., Phillips, L. A. A., Miller, C. B., Ma, J., Liu, W., Cheng, C., Schulman, B. A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808253 · Cited by 1,422
Gökbuget, N., Dombret, H., Bonifacio, M., Reichle, A., Graux, C., Faul, C., Diedrich, H., Topp, M. S., Brüggemann, M., Horst, H.-A., et al. (2018) · Blood · doi:10.1182/blood-2017-08-798322 · Cited by 858
Self-citationvan der Velden, V. H. J., Cazzaniga, G., Schrauder, A., Hancock, J., Bader, P., Panzer-Grumayer, E. R., Flohr, T., Sutton, R., Cave, H., Madsen, H. O., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404586 · Cited by 701
Foà, R., Vitale, A., Vignetti, M., Meloni, G., Guarini, A., De Propris, M. S., Elia, L., Paoloni, F., Fazi, P., Cimino, G., et al. (2011) · Blood · doi:10.1182/blood-2011-05-351403 · Cited by 462
Self-citationYanada, M., Takeuchi, J., Sugiura, I., Akiyama, H., Usui, N., Yagasaki, F., Kobayashi, T., Ueda, Y., Takeuchi, M., Miyawaki, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.2177 · Cited by 454
Fielding, A. K., Rowe, J. M., Buck, G., Foroni, L., Gerrard, G., Litzow, M. R., Lazarus, H., Luger, S. M., Marks, D. I., McMillan, A. K., et al. (2014) · Blood · doi:10.1182/blood-2013-09-529008 · Cited by 378
Vignetti, M., Fazi, P., Cimino, G., Martinelli, G., Di Raimondo, F., Ferrara, F., Meloni, G., Ambrosetti, A., Quarta, G., Pagano, L., et al. (2007) · Blood · doi:10.1182/blood-2006-10-052746 · Cited by 374
Self-citationRavandi, F., O'Brien, S., Thomas, D., Faderl, S., Jones, D., Garris, R., Dara, S., Jorgensen, J., Kebriaei, P., Champlin, R., et al. (2010) · Blood · doi:10.1182/blood-2009-12-261586 · Cited by 348
de Labarthe, A., Rousselot, P., Huguet-Rigal, F., Delabesse, E., Witz, F., Maury, S., Réa, D., Cayuela, J.-M., Vekemans, M.-C., Reman, O., et al. (2007) · Blood · doi:10.1182/blood-2006-03-011908 · Cited by 344
Rousselot, P., Coudé, M. M., Gokbuget, N., Gambacorti Passerini, C., Hayette, S., Cayuela, J.-M., Huguet, F., Leguay, T., Chevallier, P., Salanoubat, C., et al. (2016) · Blood · doi:10.1182/blood-2016-02-700153 · Cited by 327
Self-citationJabbour, E., Kantarjian, H., Ravandi, F., Thomas, D., Huang, X., Faderl, S., Pemmaraju, N., Daver, N., Garcia-Manero, G., Sasaki, K., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00207-7 · Cited by 281
Duell, J., Dittrich, M., Bedke, T., Mueller, T., Eisele, F., Rosenwald, A., Rasche, L., Hartmann, E., Dandekar, T., Einsele, H., et al. (2017) · Leukemia · doi:10.1038/leu.2017.41 · Cited by 278
Bassan, R., Rossi, G., Pogliani, E. M., Di Bona, E., Angelucci, E., Cavattoni, I., Lambertenghi-Deliliers, G., Mannelli, F., Levis, A., Ciceri, F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.1287 · Cited by 272
Self-citationRavandi, F., Othus, M., O'Brien, S. M., Forman, S. J., Ha, C. S., Wong, J. Y. C., Tallman, M. S., Paietta, E., Racevskis, J., Uy, G. L., et al. (2016) · Blood Advances · doi:10.1182/bloodadvances.2016001495 · Cited by 200
Ribera, J.-M., Oriol, A., Gonzalez, M., Vidriales, B., Brunet, S., Esteve, J., del Potro, E., Rivas, C., Moreno, M.-J., Tormo, M., et al. (2010) · Haematologica · doi:10.3324/haematol.2009.011221 · Cited by 189
Kim, D.-Y., Joo, Y.-D., Lim, S.-N., Kim, S.-D., Lee, J.-H., Lee, J.-H., Kim, D. H. (., Kim, K., Jung, C. W., Kim, I., et al. (2015) · Blood · doi:10.1182/blood-2015-03-636548 · Cited by 186
Schmidt, A., Rousselot, P. H., Chalandon, Y., et al. (2012) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2012.08.021 · Cited by 151
Delannoy, A., Delabesse, É., Lhéritier, V., Castaigné, S., Huguet, F., Raffoux, E., Garban, F., Legrand, O., Bologna, S., Dubruille, V., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404320 · Cited by 114
Chiaretti, S., Vitale, A., Vignetti, M., Piciocchi, A., Fazi, P., Elia, L., Falini, B., Ronco, F., Ferrara, F., De Fabritiis, P., et al. (2016) · Haematologica · doi:10.3324/haematol.2016.144535 · Cited by 98
Self-citationFedullo, A. L., Messina, M., Elia, L., Piciocchi, A., Gianfelici, V., Lauretti, A., Soddu, S., Puzzolo, M. C., Minotti, C., Ferrara, F., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.196055 · Cited by 88
Self-citationPfeifer, H., Raum, K., Marković, S., Nowak, V., Fey, S., Obländer, J., Pressler, J., Böhm, V., Brüggemann, M., Wunderle, L., et al. (2018) · Blood · doi:10.1182/blood-2017-07-796862 · Cited by 82
Yoon, J.-H., Yhim, H., Kwak, J., Ahn, J., Yang, D., Lee, J.-J., Kim, S.-J., Kim, J.-S., Park, S. J., Choi, C. W., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw123 · Cited by 63
Gruber, F., Mustjoki, S. M., & Porkka, K. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07666.x · Cited by 58
Elia, L., Mancini, M., Moleti, L., et al. (2003) · PubMed · Cited by 54
Self-citationChiaretti, S., Vitale, A., Elia, L., et al. (2015) · Blood · doi:10.1182/blood.v126.23.81.81 · Cited by 48
Self-citationThyagu, S., Minden, M. D., Gupta, V. K., Yee, K. W. L., Schimmer, A. D., Schuh, A. C., Lipton, J. H., Messner, H. A., Xu, W., & Brandwein, J. M. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09182.x · Cited by 27
Choi, J.-K., Cho, S., Choi, S., Kim, G. H., Lee, S., Lee, S., Kim, D., & Lee, D. (2018) · Infection and Chemotherapy · doi:10.3947/ic.2018.50.2.153 · Cited by 22
Ishiyama, K.-I., Kitawaki, T., Sugimoto, N., Sozu, T., Anzai, N., Okada, M., Nohgawa, M., Hatanaka, K., Arima, N., Ishikawa, T., et al. (2016) · Leukemia · doi:10.1038/leu.2016.174 · Cited by 17
Research works printed but not linked: 4
- 10.1038/s41375-019-0413-0 · doi:10.1038/s41375-019-0413-0
- 10.1016/j.bbmt.2016.06.022 · doi:10.1016/j.bbmt.2016.06.022
- 10.1182/blood.V124.21.2289.2289 · doi:10.1182/blood.v124.21.2289.2289
- 10.1182/blood.V130.Suppl_1.99.99 · doi:10.1182/blood.v130.suppl_1.99.99
Cited by
Emerging new therapeutic antibody derivatives for cancer treatment
Jin, S., Sun, Y., Liang, X., Gu, X., Ning, J., Xu, Y., Chen, S., & Pan, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00868-x · Cited by 459
Snowden, J. A., Sánchez-Ortega, I., Corbacioglu, S., Basak, G. W., Chabannon, C., de la Camara, R., Dolstra, H., Duarte, R. F., Glass, B., Greco, R., et al. (2022) · Bone Marrow Transplantation · doi:10.1038/s41409-022-01691-w · Cited by 379
Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies
Tian, Z., Liu, M., Zhang, Y., & Wang, X. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01084-4 · Cited by 282
Philipp, N., Kazerani, M., Nicholls, A., Vick, B., Wulf, J., Straub, T., Scheurer, M., Muth, A., Hänel, G., Nixdorf, D., et al. (2022) · Blood · doi:10.1182/blood.2022015956 · Cited by 280
T-cell-engaging bispecific antibodies in cancer
van de Donk, N. W. C. J., & Zweegman, S. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00521-4 · Cited by 267
Metadata
- Authors
- Foà, R., Bassan, R., Vitale, A., Elia, L., Piciocchi, A., Puzzolo, M.-C., Canichella, M., Viero, P., Ferrara, F., Lunghi, M., Fabbiano, F., Bonifacio, M., Fracchiolla, N., Di Bartolomeo, P., Mancino, A., De Propris, M.-S., Vignetti, M., Guarini, A., Rambaldi, A., & Chiaretti, S.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-10-22
- Volume
- 383
- Issue
- 17
- Pages
- 1613-1623
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3093938683
- Cited by
- 522
- References
- 31
- FWCI
- 47.33
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.